BlackRock Investment Management’s Heron Therapeutics HRTX Stock Holding History

BlackRock Investment Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.61M	Sell	123,064 -561	-0.5%	-$8.8K	﹤0.01%	2373
2016 Q3	$2.13M	Buy	123,625 +391	+0.3%	+$7.25K	﹤0.01%	2109
2016 Q2	$2.22M	Buy	123,234 +18,604	+18%	+$363K	﹤0.01%	2017
2016 Q1	$1.99M	Buy	104,630 +1,935	+2%	+$38.2K	﹤0.01%	2015
2015 Q4	$2.74M	Buy	102,695 +368	+0.4%	+$9.84K	﹤0.01%	1849
2015 Q3	$2.5M	Buy	102,327 +14,920	+17%	+$497K	﹤0.01%	1907
2015 Q2	$2.72M	Buy	87,407 +20,581	+31%	+$387K	﹤0.01%	1991
2015 Q1	$972K	Buy	66,826 +488	+0.7%	+$5.5K	﹤0.01%	2538
2014 Q4	$667K	Buy	66,338 +400	+0.6%	+$3.27K	﹤0.01%	2825
2014 Q3	$549K	Buy	65,938 +11,293	+21%	+$105K	﹤0.01%	2915
2014 Q2	$673K	Buy	+54,645	New	+$653K	﹤0.01%	2869

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

HCMT

Highland Capital Management (Texas) Dallas, Texas $39M AUM

BlackRock Investment Management's HRTX Position: Q4 2016 in Review

BlackRock Investment Management reduced its Heron Therapeutics (HRTX) stake by 0.45% in Q4 2016, selling an estimated $8.8K and leaving 123,064 shares worth $1.61M. The position accounts for ﹤0.01% of the portfolio, ranked #2373.

BlackRock Investment Management first reported a position in HRTX in Q2 2014 and has held it in 11 quarters since. The position peaked at $2.74M in Q4 2015. 99 funds tracked by Wall St. Rank hold HRTX as of Q4 2016.

BlackRock Investment Management held 123,064 shares of Heron Therapeutics worth $1.61M as of Q4 2016.
BlackRock Investment Management sold 561 Heron Therapeutics shares in Q4 2016, an estimated $8.8K.
Heron Therapeutics made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #2373 holding.
BlackRock Investment Management first reported a position in Heron Therapeutics in Q2 2014 and has held it in 11 quarters since.
BlackRock Investment Management's Heron Therapeutics position peaked at $2.74M in Q4 2015.
99 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.